Benzinga · Aug 25, 2026
Novavax Stock Rallies Tuesday: What's Happening?
Shares of Novavax are trading higher Tuesday morning as buying interest continues across late-stage vaccine developers.
NV
NASDAQ · NVAX
Novavax, Inc.
Healthcare · Biotechnology
$9.21
Down-$0.23 (-2.44%)
Updated Aug 27, 2026, 2:30 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.09B
- P/E ratio
- 3.18
- Dividend yield
- 0.00%
- 52-week range
- $7.15 – $11.61
- Volume
- 3.51M
- Avg. volume
- 4.26M
Price performance
NVAX price history
1M range · 21 trading sessions · Daily adjusted prices
NVAX closed at $9.21 after 21 trading sessions, up 25.48% for the selected period.
- Last close
- $9.21
- Period change
- +25.48%
- Period low
- $7.32
- Period high
- $9.44
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 26, 2026 | $9.33 | $9.44 | $9.13 | $9.21 | 3.51M |
| Aug 25, 2026 | $9.07 | $9.58 | $8.93 | $9.44 | 7.11M |
| Aug 24, 2026 | $8.87 | $8.98 | $8.26 | $8.86 | 5.58M |
| Aug 21, 2026 | $8.44 | $9.1995 | $8.435 | $8.94 | 10.45M |
| Aug 20, 2026 | $8.50 | $8.66 | $8.02 | $8.42 | 5.98M |
| Aug 19, 2026 | $8.43 | $8.83 | $8.19 | $8.79 | 11.45M |
| Aug 18, 2026 | $7.97 | $8.08 | $7.835 | $7.93 | 2.02M |
| Aug 17, 2026 | $8.05 | $8.17 | $7.95 | $8.07 | 1.93M |
| Aug 14, 2026 | $8.13 | $8.13 | $7.915 | $8.05 | 2.28M |
| Aug 13, 2026 | $8.01 | $8.23 | $7.92 | $8.14 | 3.51M |
| Aug 12, 2026 | $7.91 | $7.99 | $7.83 | $7.96 | 2.54M |
| Aug 11, 2026 | $7.92 | $8.03 | $7.78 | $7.95 | 2.61M |
| Aug 10, 2026 | $7.892 | $7.96 | $7.695 | $7.89 | 3.23M |
| Aug 7, 2026 | $7.75 | $8.086 | $7.595 | $7.95 | 5.7M |
| Aug 6, 2026 | $7.825 | $7.908 | $7.532 | $7.74 | 4.9M |
| Aug 5, 2026 | $7.71 | $7.755 | $7.54 | $7.70 | 3.63M |
| Aug 4, 2026 | $7.49 | $7.70 | $7.455 | $7.66 | 3.25M |
| Aug 3, 2026 | $7.37 | $7.6099 | $7.26 | $7.41 | 2.58M |
| Jul 31, 2026 | $7.44 | $7.49 | $7.215 | $7.32 | 3.41M |
| Jul 30, 2026 | $7.43 | $7.505 | $7.25 | $7.44 | 2.93M |
| Jul 29, 2026 | $7.29 | $7.465 | $7.235 | $7.34 | 2.33M |
Latest NVAX news
The latest Smart Investors Daily articles mentioning NVAX.
Stock researchCompany · Overview
NVAX research
Overview
Company profile and research snapshot.
Company profile
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 11, 2026 | BTIG | Buy | — |
| May 6, 2026 | TD Cowen | Hold | — |
| Feb 27, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 20, 2026 | BTIG | Buy | — |
| Nov 18, 2025 | JP Morgan | Underweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 20, 2026
Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.
Benzinga · Aug 19, 2026
Novavax Stock Moves Higher Wednesday: What's Driving the Action?
Shares of Novavax Inc (NASDAQ: NVAX) are trading higher Wednesday. The move comes as a major clinical victory in the oncology space generated widespread momentum across vaccine developers.
Yahoo · Aug 8, 2026
Novavax (NVAX) Is Up 8.6% After Beating Q2 Estimates And Expanding Big-Pharma Partnerships - What's Changed
In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside the weak year-on-year comparisons, Novavax beat analyst expectations for both revenue and earnings and highlighted progress on high-profile partnerships, including Sanofi and Pfizer, while also filing an US$82.47 million...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
